Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Clin Radiol ; 77(2): e120-e129, 2022 02.
Article in English | MEDLINE | ID: mdl-34895911

ABSTRACT

Mitral valve (MV) prolapse (MVP) is a not fully understood common MV disorder. The development of sophisticated cardiovascular magnetic resonance imaging (CMRI) sequences over the last decades has allowed a more detailed assessment and provided better understanding of the pathophysiology of MVP to guide management, interventions, and risk stratification of patients affected. This review provides an overview of the most recent insights about this multifaceted pathology, particularly regarding the emerging concepts of mitral annular disjunction (MAD), and risk of arrhythmia and sudden death associated with myocardial fibrosis. We describe the emerging role of CMRI in both diagnosis and, more importantly, risk assessment of this disease, aiming to provide a comprehensive protocol for the assessment of MVP, which could represent a practical guide to clinicians and MRI practitioners working in the field.


Subject(s)
Magnetic Resonance Imaging/methods , Mitral Valve Prolapse/diagnostic imaging , Humans , Mitral Valve/diagnostic imaging
2.
Nutr Metab Cardiovasc Dis ; 27(10): 837-849, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28954706

ABSTRACT

AIM: The aim of this review was to summarize evidence on the role of Vitamin D deficiency in heart failure (HF), from pathophysiological mechanisms to clinical effects of Vitamin D supplementation. DATA SYNTHESIS: Chronic HF secondary to left ventricular (LV) systolic dysfunction is a growing health problem, still associated with poor clinical outcome. In recent years, experimental and epidemiological evidence focused on the role of Vitamin D in HF. Cross sectional studies demonstrated that prevalence of HF is increased in patients with Vitamin D deficiency or parathyroid hormone (PTH) plasma level increase, whereas longitudinal studies showed enhanced risk of developing new HF in patients with Vitamin D deficiency. In addition, in patients with established HF, low plasma levels of Vitamin D are associated with worsening clinical outcome. Yet, clinical studies did not definitively demonstrate a benefit of Vitamin D supplementation for preventing HF or ameliorating clinical outcome in patients with established HF. CONCLUSIONS: Despite convincing experimental and epidemiological data, treatment with Vitamin D supplementation did not show clear evidence of benefit for preventing HF or influencing its clinical course. Ongoing clinical studies will hopefully shed lights on the effects of Vitamin D supplementation on clinical endpoints along the spectrum of HF.


Subject(s)
Heart Failure/epidemiology , Vitamin D Deficiency/epidemiology , Vitamin D/blood , Animals , Biomarkers/blood , Chronic Disease , Dietary Supplements , Heart Failure/mortality , Heart Failure/physiopathology , Heart Failure/therapy , Humans , Parathyroid Hormone/blood , Prevalence , Risk Factors , Treatment Outcome , Ventricular Function, Left , Ventricular Remodeling , Vitamin D/therapeutic use , Vitamin D Deficiency/blood , Vitamin D Deficiency/drug therapy , Vitamin D Deficiency/mortality
SELECTION OF CITATIONS
SEARCH DETAIL